Published in Drug Dev Res on June 01, 2009
Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science (2015) 2.14
Filovirus entry into cells - new insights. Curr Opin Virol (2012) 1.14
Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry. J Med Chem (2011) 0.95
Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res (2014) 0.94
Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect. Hum Mol Genet (2011) 0.89
siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals (Basel) (2013) 0.89
Comparative pathogenesis and systems biology for biodefense virus vaccine development. J Biomed Biotechnol (2010) 0.82
Ebola virus entry into host cells: identifying therapeutic strategies. Curr Clin Microbiol Rep (2015) 0.82
Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening. J Virol (2015) 0.77
Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob Agents Chemother (2015) 0.75
Cellular factors implicated in filovirus entry. Adv Virol (2013) 0.75
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem (1994) 14.36
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
DNA replication fidelity. Annu Rev Biochem (2000) 7.29
New uses for old drugs. Nature (2007) 5.86
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol (1998) 5.16
Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta (2007) 3.69
A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods (2007) 3.34
The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun (1991) 3.04
Generation of diversity in retroviruses. Annu Rev Genet (1990) 2.53
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res (2008) 2.30
Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology (2005) 2.25
Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature (2007) 2.19
Characterization of pseudotype VSV possessing HCV envelope proteins. Virology (2001) 2.15
Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection. J Virol (2003) 2.11
Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med (2006) 1.93
Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology (2007) 1.86
Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res (2007) 1.81
Firefly luciferase as a tool in molecular and cell biology. Anal Biochem (1988) 1.55
Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus. J Virol (2007) 1.49
Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther (2002) 1.39
Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS (2007) 1.33
Venezuelan equine encephalitis virus entry mechanism requires late endosome formation and resists cell membrane cholesterol depletion. Virology (2006) 1.31
Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS (2007) 1.27
Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat (2008) 1.22
PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol (2007) 1.16
No false start for novel pseudotyped vectors. Curr Opin Biotechnol (2002) 1.11
Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins. J Virol (2005) 1.04
Calmodulin kinase II attenuation of gene transcription by preventing cAMP response element-binding protein (CREB) dimerization and binding of the CREB-binding protein. J Biol Chem (2000) 1.04
Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother (2005) 1.01
Biochemical characterization of the fidelity of poliovirus RNA-dependent RNA polymerase. Virol J (2007) 0.99
Antiviral therapy: current concepts and practices. Clin Microbiol Rev (1992) 0.96
Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. Am J Trop Med Hyg (2006) 0.95
In-vivo activity of antivirals against exotic RNA viral infections. J Antimicrob Chemother (1984) 0.95
Enfuvirtide. Expert Opin Investig Drugs (2002) 0.95
Emerging infections--Ebola and other filoviruses. West J Med (1996) 0.93
Viruses as probes for systems analysis of cellular signalling, cytoskeleton reorganization and endocytosis. Curr Opin Microbiol (2005) 0.93
Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I. IDrugs (2005) 0.90
Phosphoinositide 3-kinase C2alpha links clathrin to microtubule-dependent movement. J Biol Chem (2006) 0.88
Side effects of HIV therapy. J Dtsch Dermatol Ges (2007) 0.87
Identification of the suppressive factors for human immunodeficiency virus type-1 replication using the siRNA mini-library directed against host cellular genes. Biochem Biophys Res Commun (2007) 0.80
Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog (2010) 2.60
Possible sexual transmission of Ebola virus - Liberia, 2015. MMWR Morb Mortal Wkly Rep (2015) 2.45
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2012) 2.13
T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A (2011) 2.12
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol (2011) 1.99
The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol (2010) 1.94
Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J Biol Chem (2004) 1.66
Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus. PLoS Pathog (2008) 1.66
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography. J Virol (2008) 1.56
Differential, type I interferon-mediated autophagic trafficking of hepatitis C virus proteins in mouse liver. Gastroenterology (2011) 1.52
Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res (2007) 1.50
Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus. J Virol (2007) 1.49
A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One (2013) 1.38
The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus. J Virol (2010) 1.36
Single-particle cryo-electron microscopy of Rift Valley fever virus. Virology (2009) 1.34
Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding. PLoS Pathog (2010) 1.32
Venezuelan equine encephalitis virus entry mechanism requires late endosome formation and resists cell membrane cholesterol depletion. Virology (2006) 1.31
Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. J Virol (2013) 1.29
T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother (2010) 1.27
Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology (2008) 1.23
A proposal to change existing virus species names to non-Latinized binomials. Arch Virol (2010) 1.18
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
A catalytically and genetically optimized beta-lactamase-matrix based assay for sensitive, specific, and higher throughput analysis of native henipavirus entry characteristics. Virol J (2009) 1.15
Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection. J Clin Microbiol (2004) 1.11
Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers. Emerg Infect Dis (2009) 1.11
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Detection of severe fever with thrombocytopenia syndrome virus by reverse transcription-cross-priming amplification coupled with vertical flow visualization. J Clin Microbiol (2012) 1.09
Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology (2010) 1.08
Solution structure and structural dynamics of envelope protein domain III of mosquito- and tick-borne flaviviruses. Biochemistry (2004) 1.07
Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J Virol (2012) 1.06
A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog (2013) 1.05
Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism. Virology (2007) 1.05
Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins. J Virol (2005) 1.04
Analysis of the complete genome of the tick-borne flavivirus Omsk hemorrhagic fever virus. Virology (2003) 1.02
Rapid and sensitive detection of retrovirus entry by using a novel luciferase-based content-mixing assay. J Virol (2004) 1.02
Novel, rapid assay for measuring entry of diverse enveloped viruses, including HIV and rabies. J Virol Methods (2006) 1.02
A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology (2009) 1.01
The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J Virol (2013) 1.00
Determining functionally important amino acid residues of the E1 protein of Venezuelan equine encephalitis virus. J Mol Model (2006) 1.00
gammadelta T cells promote the maturation of dendritic cells during West Nile virus infection. FEMS Immunol Med Microbiol (2010) 1.00
Respiratory syncytial virus F envelope protein associates with lipid rafts without a requirement for other virus proteins. J Virol (2006) 0.99
Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci U S A (2011) 0.99
The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine. J Virol (2012) 0.99
Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever Sicilian virus. PLoS Negl Trop Dis (2013) 0.98
Recent progress in henipavirus research: molecular biology, genetic diversity, animal models. Antiviral Res (2012) 0.97
Release of dengue virus genome induced by a peptide inhibitor. PLoS One (2012) 0.97
An assembly model of rift valley Fever virus. Front Microbiol (2012) 0.97
Effective suppression of Dengue fever virus in mosquito cell cultures using retroviral transduction of hammerhead ribozymes targeting the viral genome. Virol J (2009) 0.96
Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. Am J Trop Med Hyg (2006) 0.95
A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. Mol Pharm (2011) 0.95
Venezuelan equine encephalitis virus infection of mosquito cells requires acidification as well as mosquito homologs of the endocytic proteins Rab5 and Rab7. Virology (2007) 0.95
Iquitos virus: a novel reassortant Orthobunyavirus associated with human illness in Peru. PLoS Negl Trop Dis (2011) 0.95
Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol (2013) 0.94
Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol (2009) 0.93
Sub-genomic replicon and virus-like particles of Omsk hemorrhagic fever virus. Arch Virol (2009) 0.93
Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains. J Virol (2012) 0.92
Chemotactic and inflammatory responses in the liver and brain are associated with pathogenesis of Rift Valley fever virus infection in the mouse. PLoS Negl Trop Dis (2012) 0.92
Mouse mammary tumor virus uses mouse but not human transferrin receptor 1 to reach a low pH compartment and infect cells. Virology (2008) 0.91
Clinical evaluation of highly pathogenic tick-borne flavivirus infection in the mouse model. J Med Virol (2009) 0.91
Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. Virology (2005) 0.91
Comparative analysis of immune responses to Russian spring-summer encephalitis and Omsk hemorrhagic fever viruses in mouse models. Virology (2010) 0.90
A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity. Clin Vaccine Immunol (2009) 0.88
Structure of the envelope protein domain III of Omsk hemorrhagic fever virus. Virology (2006) 0.87
Oligomerization of Uukuniemi virus nucleocapsid protein. Virol J (2010) 0.87
Tick-borne Encephalitis Vaccines. J Bioterror Biodef (2011) 0.85
Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin. Arch Virol (2011) 0.85
SRC regulates constitutive internalization and rapid resensitization of a cholecystokinin 2 receptor splice variant. J Biol Chem (2005) 0.84
Crystallization and preliminary X-ray diffraction analysis of Langat virus envelope protein domain III. Acta Crystallogr D Biol Crystallogr (2003) 0.84
Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine. Mol Pharm (2013) 0.84
Construction of an infectious cDNA clone for Omsk hemorrhagic fever virus, and characterization of mutations in NS2A and NS5. Virus Res (2010) 0.83
Critical role for the host GTPase-activating protein ARAP2 in InlB-mediated entry of Listeria monocytogenes. Infect Immun (2010) 0.83
CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells. Int J Cancer (2010) 0.82
Luminal-applied flagellin is internalized by polarized intestinal epithelial cells and elicits immune responses via the TLR5 dependent mechanism. PLoS One (2011) 0.82
Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice. J Gen Virol (2013) 0.82
VIPR: A probabilistic algorithm for analysis of microbial detection microarrays. BMC Bioinformatics (2010) 0.81
1H, 13C and 15N resonance assignments for domain III of the West Nile virus envelope protein. J Biomol NMR (2004) 0.80
AMP-activated protein kinase is required for the macropinocytic internalization of ebolavirus. J Virol (2012) 0.80
Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles. J Virol Methods (2010) 0.80
A critical determinant of neurological disease associated with highly pathogenic tick-borne flavivirus in mice. J Virol (2014) 0.80
Japanese Encephalitis Vaccines. J Bioterror Biodef (2011) 0.79
GRB2 interaction with the ecotropic murine leukemia virus receptor, mCAT-1, controls virus entry and is stimulated by virus binding. J Virol (2011) 0.79
Differential cytokine responses from primary human Kupffer cells following infection with wild-type or vaccine strain yellow fever virus. Virology (2011) 0.78
Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes. Virus Res (2013) 0.78